# Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

> **NCT04203498** · PHASE3 · TERMINATED · sponsor: **Jazz Pharmaceuticals** · enrollment: 139 (actual)

## Conditions studied

- Multiple Sclerosis (MS)

## Interventions

- **DRUG:** Nabiximols
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04203498
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-01
- **Primary completion:** 2023-02-10
- **Final completion:** 2023-02-28
- **Target enrollment:** 139 (ACTUAL)
- **Why stopped:** This study was terminated based on a business decision by the Sponsor.
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04203498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04203498, "Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04203498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*